Your browser doesn't support javascript.
loading
Treatment of Graves' disease in Brazil: results of a survey among endocrinologists.
Villagelin, Danilo; Mazeto, Glaucia M F S; Mesa, Cléo Otaviano; Ramos, Helton Estrela; Scheffel, Rafael Selbach; Chiamolera, Maria Izabel; Perini, Nicolas; Ronconi, Thiago Luis; Texeira, Patricia.
Afiliação
  • Villagelin D; Pontifícia Universidade Católica de Campinas - Endocrinologia, Campinas SP, Brasil.
  • Mazeto GMFS; Universidade Estadual Paulista, São Paulo, SP, Brasil.
  • Mesa CO; Universidade Federal do Paraná, Hospital de Clínicas - Serviço de Endocrinologia e Metabologia, Curitiba, PR, Brasil.
  • Ramos HE; Universidade Federal da Bahia - Biorregulação, Salvador, BA, Brasil.
  • Scheffel RS; Universidade Federal da Bahia - Instituto de Biorregulação, Saúde e Ciência, Salvador, BA, Brasil.
  • Chiamolera MI; Hospital de Clínicas de Porto Alegre - Seção de Tireoide, Porto Alegre, RS, Brasil.
  • Perini N; Universidade Federal de São Paulo - Divisão de Endocrinologia, São Paulo, SP, Brasil.
  • Ronconi TL; Pontifícia Universidade Católica de Campinas - Endocrinologia, Campinas SP, Brasil, nicolas_perini@hotmail.com.
  • Texeira P; Hospital da Pontifícia Universidade Católica de Campinas, Campinas, SP, Brasil.
Arch Endocrinol Metab ; 67(6): e000657, 2023 Jun 19.
Article em En | MEDLINE | ID: mdl-37364155
ABSTRACT

Objective:

The objective of the study was to determine how physicians in Brazil manage Graves' disease in different scenarios including extrathyroidal manifestations. Materials and

methods:

This study was conducted via a digital survey. The respondents (n = 573) answered multiple-choice questions based on a clinical case and variations of the case regarding laboratory and imaging evaluation, treatment choice, and follow-up.

Results:

The preferred initial treatment chosen by 95% of the respondents was ATD with a preferred treatment duration of 18-24 months. For 5% of the respondents, RAI was the initial treatment of choice. None of the respondents chose thyroidectomy. When presented with a patient with a desire for pregnancy in the near future, most respondents (69%) opted for ATD as the initial treatment. For a patient with signs of mild to moderate Graves' orbitopathy, ATD remained the initial therapy for 93.9% of the respondents. For patients initially treated with ATD with disease recurrence after ATD interruption, most respondents (60%) chose definitive treatment with RAI. A similar survey published in 2011 by Burch and cols. had results comparable to those of the present survey but with a higher proportion of respondents choosing RAI (45% in the 2011 survey versus 5% in the present survey).

Conclusion:

Brazilian endocrinologists choose ATD as the initial management of Graves' disease, and most choose RAI as a definitive treatment for a patient with relapse after ATD therapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Graves / Oftalmopatia de Graves Limite: Female / Humans / Pregnancy País como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Graves / Oftalmopatia de Graves Limite: Female / Humans / Pregnancy País como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2023 Tipo de documento: Article